Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 583, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ijpharm.2020.119352
Keywords
Monoclonal antibody; Nitric oxide; S-nitrosothiol; EPR effect
Categories
Funding
- MEXT, Japan [18K19148]
- JSPS [17J04646]
- Advanced Graduate Course on Molecular Systems for Devices (Kyushu University)
- Grants-in-Aid for Scientific Research [18K19148, 17J04646] Funding Source: KAKEN
Ask authors/readers for more resources
Although monoclonal antibodies (mAbs) have revolutionized cancer treatment, their accumulation in solid tumors is limited and requires improvement to enhance therapeutic efficacy. Here we developed a strategy to modify mAb with a donor of nitric oxide (NO) because NO functions to vasodilate as well as to enhance the permeability of vascular endothelium, which will contribute to enhancing the tumor accumulation of mAb. We selected S-nitrosothiol as a NO donor and established the procedure to modify S-nitrosothiol group on mAb under ambient conditions. The modified mAb (Ab-SNO) thus obtained released NO in a preferable speed and maintained its original properties such as binding affinity to a target antigen and efficacy to induce antibody-dependent cellular cytotoxicity. We demonstrated that Ab-SNO enhanced the tumor accumulation of co-administered proteins such as antibody and serum albumin.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available